Curcumin reduces the toxic effects of iron loading in rat liver epithelial cells

Liver International

Volumn 29, Issue 1, 2009, Pages 63-72

  Messner, Donald J ^a,b   Sivam, Gowsala ^a   Kowdley, Kris V ^b  

^a BASTYR UNIVERSITY   (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

Curcumin; Iron; Liver disease; Oxidative stress; Stress activated MAP kinase

Indexed keywords

8 QUINOLINOL; ACETYLCYSTEINE; ALPHA TOCOPHEROL; CURCUMIN; DEFEROXAMINE; FERRIC AMMONIUM CITRATE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN C JUN; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; BIOAVAILABILITY; CELL STRESS; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; EPITHELIUM CELL; FLUORESCENCE ANALYSIS; IC 50; IRON OVERLOAD; IRON TRANSPORT; LIVER CELL; LIVER TOXICITY; NONHUMAN; OXIDATIVE STRESS; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; CELLS, CULTURED; CURCUMIN; DEFEROXAMINE; EPITHELIAL CELLS; FERRIC COMPOUNDS; INHIBITORY CONCENTRATION 50; LIVER; OXIDATIVE STRESS; QUATERNARY AMMONIUM COMPOUNDS; RATS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES;

EID: 57749178645     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01793.x     Document Type: Article

References (61)

1. Stal P. Iron as a hepatotoxin. Dig Dis 1995; 13: 205-22.
2. Eaton JW, Qian M. Molecular bases of cellular iron toxicity. Free Radic Biol Med 2002; 32: 833-40.
3. Haber F, Weiss J. The catalytic decompostion of hydrogen peroxide by iron salts. Proc R Soc Lond Sect A 1934; 147: 332-51.
4. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem 2005; 12: 1161-208.
5. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004; 44: 239-67.
6. Fleming RE, Sly WS. Mechanisms of iron accumulation in hereditary hemochromatosis. Annu Rev Physiol 2002; 64: 663-80.
7. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: Molecular control of mammalian iron metabolism. Cell 2004; 117: 285-97.
8. Andrews NC, Schmidt PJ. Iron homeostasis. Annu Rev Physiol 2007; 69: 69-85.
9. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004; 127 (Suppl. 1): S79-86.
10. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006; 71: 1397-421.
11. Luper S. A review of plants used in the treatment of liver disease: Part two. Altern Med Rev 1999; 4: 178-88.
12. Sharma RA, Gescher AJ, Steward WP. Curcumin: The story so far. Eur J Cancer 2005; 41: 1955-68.
13. Qureshi S, Shah AH, Ageel AM. Toxicity studies on Alpinia galanga and Curcuma longa. Planta Med 1992; 58: 124-7.
14. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21: 2895-900.
15. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res 2004; 10: 6847-54.
16. Lao CD, Ruffin MT, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006; 6: 10.
17. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: The Indian solid gold. Adv Exp Med Biol 2007; 595: 1-75.
18. Kiso Y, Suzuki Y, Watanabe N, Oshima Y, Hikino H. Antihepatotoxic principles of Curcuma longa rhizomes. Planta Med 1983; 49: 185-7.
19. Deshpande SS, Lalitha VS, Ingle AD, Raste AS, Gadre SG, Maru GB. Subchronic oral toxicity of turmeric and ethanolic turmeric extract in female mice and rats. Toxicol Lett 1998; 95: 183-93.
20. Soni KB, Lahiri M, Chackradeo P, Bhide SV, Kuttan R. Protective effect of food additives on aflatoxin-induced mutagenicity and hepatocarcinogenicity. Cancer Lett 1997; 115: 129-33.
21. Chuang SE, Kuo ML, Hsu CH, et al. Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis. Carcinogenesis 2000; 21: 331-5.
22. Thapliyal R, Naresh KN, Rao KV, Maru GB. Inhibition of nitrosodiethylamine-induced hepatocarcinogenesis by dietary turmeric in rats. Toxicol Lett 2003; 139: 45-54.
23. Leclercq IA, Farrell GC, Sempoux C, dela Pena A, Horsmans Y. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol 2004; 41: 926-34.
24. Bruck R, Ashkenazi M, Weiss S, et al. Prevention of liver cirrhosis in rats by curcumin. Liver Int 2007; 27: 373-83.
25. Sreejayan Rao MN. Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol 1994; 46: 1013-6.
26. Baum L, Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J Alzheimers Dis 2004; 6: 367-77; discussion 369-443.
27. Jiao Y, Wilkinson J, Christine Pietsch E, et al. Iron chelation in the biological activity of curcumin. Free Radic Biol Med 2006; 40: 1152-60.
28. Swierenga SH, Whitfield JF, Boynton AL, et al. Regulation of proliferation of normal and neoplastic rat liver cells by calcium and cyclic AMP. Ann NY Acad Sci 1980; 349: 294-311.
29. Blouin R, Blouin MJ, Royal I, et al. Cytokeratin 14 expression in rat liver cells in culture and localization in vivo. Differentiation 1992; 52: 45-54.
30. Huang RP, Peng A, Golard A, et al. Hydrogen peroxide promotes transformation of rat liver non-neoplastic epithelial cells through activation of epidermal growth factor receptor. Mol Carcinogr 2001; 30: 209-17.
31. Boynton AL, Kleine LP, Whitfield JF. Relation between colony formation in calcium-deficient medium, colony formation in soft agar, and tumor formation by T51B rat liver cells. Cancer Lett 1984; 21: 293-302.
32. Huang RP, Peng A, Hossain MZ, Fan Y, Jagdale A, Boynton AL. Tumor promotion by hydrogen peroxide in rat liver epithelial cells. Carcinogenesis 1999; 20: 485-92.
33. Messner DJ, Ao P, Jagdale AB, Boynton AL. Abbreviated cell cycle progression induced by the serine/threonine protein phosphatase inhibitor okadaic acid at concentrations that promote neoplastic transformation. Carcinogenesis 2001; 22: 1163-72.
34. Messner DJ, Kowdley KV. Neoplastic transformation of rat liver epithelial cells is enhanced by non-transferrin-bound iron. BMC Gastroenterol 2008; 8: 2.
35. Grootveld M, Bell JD, Halliwell B, Aruoma OI, Bomford A, Sadler PJ. Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J Biol Chem 1989; 264: 4417-22.
36. Wheby MS, Umpierre G. Effect of transferrin saturation on iron absorption in man. N Engl J Med 1964; 271: 1391-5.
37. Leanderson P, Tagesson C. Iron bound to the lipophilic iron chelator, 8-hydroxyquinoline, causes DNA strand breakage in cultured lung cells. Carcinogenesis 1996; 17: 545-50.
38. Zhou W, Merrick BA, Khaledi MG, Tomer KB. Detection and sequencing of phosphopeptides affinity bound to immobilized metal ion beads by matrix-assisted laser desorption/ionization mass spectrometry. J Am Soc Mass Spectrom 2000; 11: 273-82.
39. Scheiber-Mojdehkar B, Zimmermann I, Dresow B, Goldenberg H. Differential response of non-transferrin bound iron uptake in rat liver cells on long-term and short-term treatment with iron. J Hepatol 1999; 31: 61-70.
40. Messner DJ, Romeo C, Boynton A, Rossie S. Inhibition of PP2A, but not PP5, mediates p53 activation by low levels of okadaic acid in rat liver epithelial cells. J Cell Biochem 2006; 99: 241-55.
41. Sieuwerts AM, Klijn JG, Peters HA, Foekens JA. The MTT tetrazolium salt assay scrutinized: How to use this assay reliably to measure metabolic activity of cell cultures in vitro for the assessment of growth characteristics, IC50-values and cell survival. Eur J Clin Chem Clin Biochem 1995; 33: 813-23.
42. Bernabe-Pineda M, Ramirez-Silva MT, Romero-Romo MA, Gonzalez-Vergara E, Rojas-Hernandez A. Spectrophotometric and electrochemical determination of the formation constants of the complexes Curcumin-Fe(III)-water and Curcumin-Fe(II)-water. Spectrochim Acta A Mol Biomol Spectrosc 2004; 60: 1105-13.
43. Caris C, Baret P, Beguin C, Serratrice G, Pierre JL, Laulhere JP. Metabolization of iron by plant cells using O-Trensox, a high-affinity abiotic iron-chelating agent. Biochem J 1995; 312(Part 3): 879-85.
44. d'Hardemare Adu M, Torelli S, Serratrice G, Pierre JL. Design of iron chelators: Syntheses and iron (III) complexing abilities of tripodal tris-bidentate ligands. Biometals 2006; 19: 349-66.
45. Mouralian C, Buss JL, Stranix B, Chin J, Ponka P. Mobilization of iron from cells by hydroxyquinoline-based chelators. Biochem Pharmacol 2005; 71: 214-22.
46. Ding WQ, Liu B, Vaught JL, Yamauchi H, Lind SE. Anticancer activity of the antibiotic clioquinol. Cancer Res 2005; 65: 3389-95.
47. Wardman P. Fluorescent and luminescent probes for measurement of oxidative and nitrosative species in cells and tissues: Progress, pitfalls, and prospects. Free Radic Biol Med 2007; 43: 995-1022.
48. Fraga CG, Oteiza PI. Iron toxicity and antioxidant nutrients. Toxicology 2002; 180: 23-32.
49. Reddy AC, Lokesh BR. Studies on the inhibitory effects of curcumin and eugenol on the formation of reactive oxygen species and the oxidation of ferrous iron. Mol Cell Biochem 1994; 137: 1-8.
50. Reddy AC, Lokesh BR. Effect of curcumin and eugenol on iron-induced hepatic toxicity in rats. Toxicology 1996; 107: 39-45.
51. Fang J, Lu J, Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin: A novel molecular mechanism for its anticancer activity. J Biol Chem 2005; 280: 25284-90.
52. Woo JH, Kim YH, Choi YJ, et al. Molecular mechanisms of curcumin-induced cytotoxicity: Induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 2003; 24: 1199-208.
53. Syng-Ai C, Kumari AL, Khar A. Effect of curcumin on normal and tumor cells: Role of glutathione and bcl-2. Mol Cancer Ther 2004; 3: 1101-8.
54. Fujisawa S, Atsumi T, Ishihara M, Kadoma Y. Cytotoxicity, ROS-generation activity and radical-scavenging activity of curcumin and related compounds. Anticancer Res 2004; 24: 563-9.
55. Susan M, Rao MN. Induction of glutathione S-transferase activity by curcumin in mice. Arzneimittelforschung 1992; 42: 962-4.
56. Balogun E, Hoque M, Gong P, et al. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J 2003; 371(Part 3): 887-95.
57. Dinkova-Kostova AT, Talalay P. Relation of structure of curcumin analogs to their potencies as inducers of Phase 2 detoxification enzymes. Carcinogenesis 1999; 20: 911-4.
58. Weber WM, Hunsaker LA, Gonzales AM, et al. TPA-induced up-regulation of activator protein-1 can be inhibited or enhanced by analogs of the natural product curcumin. Biochem Pharmacol 2006; 72: 928-40.
59. Weber WM, Hunsaker LA, Roybal CN, et al. Activation of NFkappaB is inhibited by curcumin and related enones. Bioorg Med Chem 2006; 14: 2450-61.
60. Ireson C, Orr S, Jones DJ, et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 2001; 61: 1058-64.
61. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005; 18: 277-87.